Ingredient Formulations of Category I drugs

@2336. CHOWDHARY RAM SEWAK : Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 693 given in the Rajya Sabha on the 2nd May, 1989 and state:

(a) whether it is a fact that Category I drugs consist of single ingredient as well as multiple ingredient formulations;

(b) the names of the multiple ingredient formulations used for diseases under the National Health Programme;

(c) what is the composition of each drug and the disease for which each is used;

(d) on what basis the Ministry of Health and Family Welfare has come to the conclusion that Category-I drugs consist of single bulk drug only;

(e) whether it is a fact that the criteria for identification of Category I drugs is the therapeutic use of formulations;

(f) whether it is also a fact that Chloroquin and Tetracycline combination is being marketed in the country ;

(g) if so, what is the therapeutic use of this combination and whether this is used for Malaria; and

(h) what is the rationale behind decontrolling Oral Rehydration Salts when the same are used for two National Health Programme ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL) : (a) to (e) All multi ingredient formulations containing any of the bulk drugs specified in Schedule I of the DPCO, 1987 fall under Category I of the DPCO, 1987.

(f) and (g) These details are not readily available.

(h) The Oral Rehydration Salt (ORS) has been price decontrolled on the recommendation of the Kelkar Committee contained in their supplementary report.

@Previously Unstarred Question 1631, transferred from the 1st August, 1989.

Production of Drugs based on Oxyphenyl-Butazone and Phenylbutazone

@@2337. SHRI CHITTA BASU : Will the Minister of INDUSTRY be pleased to state:

(a) what are the names of five leading brands of drugs along with the names of producers based on Oxyphenyl-butazone and Phenylbutazone being marketed in India;

(b) what is the price of each brand of each drug;

(c) whether it is a fact that both these drugs have been kept outside price control on the plea of the representatives of the Ministry of Health and Family Welfare that these drugs are harmful and injurious and are being withdrawn shortly; and

(d) if so, what is the exact position of each drug; and what corrective steps are being taken in this regard ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS

@@Previously Unstarred Question 1638, transferred from the 1st August, 1989.

AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL) : (a) and (b) These details are not available as sales turn over of a formulations is not monitored.

(c) and (d) While considering the drugs for possible inclusion in the second schedule of DPCO, 1987, the Kelkar Committee could not reach any conclusion in regard to Oxyphenbutazone and Phenylbutazone.

Import of Triprolidine Polymixin-B Sulphate and Glipizide

@2338. SHRI ASHOK NATH VERMA : Will the Minister of INDUSTRY be pleased to refer to answer to Unstarred Question 741 given in the Rajya Sabha on the 2nd May, 1989 and state:

(a) whether it is a fact that the value of imports of Triprolidine, Polymixin-B Sulphate and Glipizide varies from Rs. 36 lakhs to Rs. 208 lakhs per annum;

(b) whether it is also a fact that certain companies have monopoly production of formulations based on these drugs;

(c) whether it is also a fact that none of these bulk drugs fulfils any of the exclusion criteria as laid down by the Kelkar Committee; and

(d) the grounds on which the Ministry of Health and Family Welfare agreed to the price decontrol of these drugs ?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL) : (a) The required details to the extent available have already been given in reply to unstarred question 741 referred to in the question.

(b) Production of formulations is not monitored.

(c) and (d) The drugs referred to in part (a) in the question were excluded from price control under DPCO, 1987 as per recommendations of the Kelkar Committee.

Production of Glybenclamide

@@2339. SHRI SANTOSH KUMAR SAHU:
DR. (SMT.) SAROJINI MAHISHI:

Will the Minister of INDUSTRY be pleased to state:

(a) whether Glybenclamide is an essential drug according to the opinion of the Ministry of Health and Family Welfare;

(b) whether it is a fact that the production thereof is monopolised by one company;

(c) what was the price of leading brand Daonil Tablets based on this drug before decontrol and what is the present price;

(d) what is the basis on which two expert members of the Ministry of Health and Family Welfare on Kelkar Committee agreed to its decontrol on the ground that this drug is not essential;

(e) whether his Ministry have called for the reasons; and

(f) if so, what are the details thereof and if not, the reasons therefor ?

@Previously Unstarred Question 1640, transferred from the 1st August, 1989.

@@Previously Unstarred Question 1673, transferred from the 1st August, 1989.